Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.

ABSTRACT:

SUBMITTER: Younes A 

PROVIDER: S-EPMC5494693 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature